These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36998454)

  • 21. Evaluation of tyrosine kinase inhibitors combined with antiprogrammed cell death protein 1 antibody in tyrosine kinase inhibitor-responsive patients with microsatellite stable/proficient mismatch repair metastatic colorectal adenocarcinoma: protocol for open-label, single-arm trial.
    Dong Q; Diao Y; Sun X; Zhou Y; Ran J; Zhang J
    BMJ Open; 2022 Apr; 12(4):e049992. PubMed ID: 35379611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Multicenter real-world study on safety and efficacy of neoadjuvant therapy in combination with immunotherapy for colorectal cancer].
    Liu XZ; Xiong Z; Xiao BY; Yu GY; Li YJ; Yao YF; Tao KX; Ding PR; Zhang W; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Mar; 25(3):219-227. PubMed ID: 35340171
    [No Abstract]   [Full Text] [Related]  

  • 23. Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases.
    Guo Y; Zhang W; Ying J; Zhang Y; Pan Y; Qiu W; Fan Q; Xu Q; Ma Y; Wang G; Guo J; Su W; Fan S; Tan P; Wang Y; Luo Y; Zhou H; Li J
    Eur J Cancer; 2023 Mar; 181():26-37. PubMed ID: 36628898
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Case of Systemic Severe Bullous Pemphigoid Caused by Long-Term Sintilimab Treatment for Renal Cell Carcinoma.
    He J; Duan X; Liu T; Yang H; Jiang J; Mu Y
    Clin Cosmet Investig Dermatol; 2022; 15():1611-1614. PubMed ID: 35975195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Neoadjuvant immunotherapy in microsatellite stability or mismatch repair proficient colorectal cancer].
    Zhang JW; Deng YH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Mar; 25(3):193-198. PubMed ID: 35340167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of bullous pemphigoid following radiation therapy combined with nivolumab for renal cell carcinoma: A case report of abscopal toxicities.
    Huynh LM; Bonebrake BT; DiMaio DJ; Baine MJ; Teply BA
    Medicine (Baltimore); 2021 Dec; 100(49):e28199. PubMed ID: 34889301
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Programmed cell death-1 inhibitor combination treatment for recurrent proficient mismatch repair/ miscrosatellite-stable type endometrial cancer: A case report.
    Zhai CY; Yin LX; Han WD
    World J Clin Cases; 2022 Jul; 10(21):7474-7482. PubMed ID: 36157989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report.
    Mari R; Guerin M; Vicier C; Walz J; Bonnet N; Pignot G; Gravis G
    Front Immunol; 2022; 13():984132. PubMed ID: 36189265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
    Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
    [No Abstract]   [Full Text] [Related]  

  • 30. Identification of the molecular characteristics associated with microsatellite status of colorectal cancer patients for the clinical application of immunotherapy.
    Fu J; Jin X; Chen W; Chen Z; Wu P; Xiao W; Liu Y; Deng S
    Front Pharmacol; 2023; 14():1083449. PubMed ID: 36814498
    [No Abstract]   [Full Text] [Related]  

  • 31. Recurrent Gallbladder Carcinoma With pMMR/MSS Achieved a Complete Response Following Camrelizumab Combined With Apatinib: A Case Report.
    Zhong L; Liu X; Li Z; Zhang X; Wang Y; Peng W
    Front Oncol; 2021; 11():783158. PubMed ID: 35096582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metastatic Colorectal Cancer Patient with Microsatellite Stability and Germline BRAC2 Mutation Shows a Complete Response to Olaparib in Combination with a PD-1 Inhibitor and Bevacizumab: A Case Report and Review of the Literature.
    Song M; Zeng X; Wu Q; Huang J; Dong J; Shao L; Sun Z; Lin Y; Chen S
    Life (Basel); 2023 May; 13(5):. PubMed ID: 37240828
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
    Gu YC; Liu Y; Xie C; Cao BS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of immune checkpoint inhibitors combined with bevacizumab in MSS/pMMR advanced colorectal cancer after first-line treatment failure.
    Chen X; Li W; Lei X; Li Z; Guo Q; Ma X; Luo Y; Wang L
    Front Oncol; 2024; 14():1429095. PubMed ID: 39188683
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance.
    Chen KH; Yuan CT; Tseng LH; Shun CT; Yeh KH
    J Hematol Oncol; 2016 Mar; 9():29. PubMed ID: 27012666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term survival of a patient with microsatellite-stable refractory colorectal cancer with regorafenib and PD-1 inhibitor sintilimab: a case report and review of literature.
    Zhang Y; Zhang F; Zhao L; Fu X; Shang Y; Gao Q
    BMC Gastroenterol; 2021 Oct; 21(1):399. PubMed ID: 34688262
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Case Report: A Rare Case of Pembrolizumab-Induced Bullous Pemphigoid.
    Zhang X; Sui D; Wang D; Zhang L; Wang R
    Front Immunol; 2021; 12():731774. PubMed ID: 34594337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term response to sintilimab, bevacizumab and chemotherapy in heavily pretreated microsatellite stable colon cancer.
    Cui Z; Wang Q; Deng M; Meng E; Liu S; Niu B; Han Q
    Immunotherapy; 2023 Feb; 15(3):127-133. PubMed ID: 36722149
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A case of drug-induced bullous pemphigoid secondary to immunotherapy treated with upadacitinib: A case report.
    Gresham LM; Kirchhof MG
    SAGE Open Med Case Rep; 2023; 11():2050313X231160926. PubMed ID: 36968984
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mucous Membrane Pemphigoid, Bullous Pemphigoid, and Anti-programmed Death-1/ Programmed Death-Ligand 1: A Case Report of an Elderly Woman With Mucous Membrane Pemphigoid Developing After Pembrolizumab Therapy for Metastatic Melanoma and Review of the Literature.
    Zumelzu C; Alexandre M; Le Roux C; Weber P; Guyot A; Levy A; Aucouturier F; Mignot-Grootenboer S; Caux F; Maubec E; Prost-Squarcioni C
    Front Med (Lausanne); 2018; 5():268. PubMed ID: 30320114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.